TEE
ADVM

Tibra Equities Europe’s Adverum Biotechnologies ADVM Stock Holding History

Tibra Equities Europe’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,860
Closed -$265K – 180
2019
Q3 		$265K Buy
+4,860
New +$548K 0.03% 189
2018
Q2 		– Sell
-10,806
Closed -$627K – 118
2018
Q1 		$627K Buy
+10,806
New +$673K 0.11% 102

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KL
Kam Lawrence $97.4M AUM
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Tibra Equities Europe's ADVM Position: Q4 2019 in Review

Tibra Equities Europe sold out of Adverum Biotechnologies (ADVM) in Q4 2019, closing a stake of 4,860 shares — an estimated $265K sold.

Tibra Equities Europe first reported a position in ADVM in Q1 2018 and held it in 2 quarters. The position peaked at $627K in Q1 2018. 116 funds tracked by Wall St. Rank hold ADVM as of Q4 2019.

  • Tibra Equities Europe reported no remaining Adverum Biotechnologies position as of Q4 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 4,860 Adverum Biotechnologies shares in Q4 2019, an estimated $265K.
  • Tibra Equities Europe first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 2 quarters.
  • Tibra Equities Europe's Adverum Biotechnologies position peaked at $627K in Q1 2018.
  • 116 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2019.

Based on Tibra Equities Europe's 13F filing for Q4 2019, filed 14 Feb 2020.